Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the fourth quarter and year ended ...

Rigel Pharmaceuticals (NASDAQ:RIGL) detailed record commercial performance for the fourth quarter and full year 2025, while outlining plans to pursue additional in-licensing opportunities and advance ...

Rigel Pharmaceuticals (RIGL) stock hits a 4-month low as 2026 revenue guidance signals a topline contract due to falling contract revenue. Read more here.

Rigel Pharmaceuticals is back in focus as analysts update their narrative around the stock, with the fair value price target holding steady at $51.6. Supportive voices point to this unchanged figure ...

Return on Assets (ROA): Rigel Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 12.42%, the company showcases ...

Greetings, and welcome to the Rigel Pharmaceuticals Financial Conference Call for the Fourth Quarter and Full Year 2025. [Operator Instructions] As a reminder, this conference is being recorded. It is ...

Four months ago, Rigel Pharmaceuticals spent just $2 million—plus ponying up another $233 million in potential milestones—to acquire Forma Therapeutics’ leukemia drug Rezlidhia. On Thursday, Rigel got ...

SOUTH SAN FRANCISCO, Calif. (AP) — Rigel Pharmaceuticals Inc. (RIGL) on Tuesday reported net income of $268.1 million in its fourth quarter.

Rigel’s IRAK1/4 inhibitor, R289, has shown promising results in a Phase 1b trial for relapsed/refractory lower-risk myelodysplastic syndrome (LR-MDS). The initial data presented at ASH 2024 ...

Rigel Pharmaceuticals RIGL is scheduled to report third-quarter 2025 results on Nov. 4, after market close. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $61.6 ...